Navigation Links
New study suggests Rx estrogen delivery through the skin may show safety benefits as opposed to oral delivery
Date:3/26/2009

NEW YORK, NY (March 25, 2009) Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by researchers at NYU Langone Medical Center and was published in the latest issue of Menopause: The Journal of the North American Menopause Society.

Prescription transdermal estrogen therapy is bioidentical to estrogen produced by a woman's ovaries before menopause and delivered through the skin. Transdermal estrogen is available in a variety of formulations which have been quality controlled and approved safe and effective by the United States Food and Drug Administration (FDA).

The team at NYU Langone sought to determine the effects of delivery of estrogen therapy on postmenopausal women. Blood obtained from 84 postmenopausal women was tested for clotting activity before and after administration of oral or transdermal estrogen for a period of eight weeks. Women with borderline clotting issues showed "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after transdermal estrogen therapy.

"Venous thromboembolic complications or blood clots represent an established risk factor of estrogen therapy, and evidence is now mounting that the route of estrogen administration influences this risk," said researcher Lila Nachtigall, M.D., Director of the Women's Wellness Program at NYU. "These new data on the safety of transdermal HT delivery may prove to be useful information for postmenopausal women deciding whether to take estrogen therapy and whether to take it orally or through the skin."

The research team studied platelet activity in the study participants' blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further concluded that the ability to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to help physicians determine which women may be at the least risk to benefit from estrogen therapy.

"The effect of estrogen therapy on cardiovascular risk remains a point of controversy; however, these data suggest that estrogen delivered transdermally may not increase the likelihood of clotting for women who are at borderline risk," said Dr. Nachtigall. "This study supports the emerging data suggesting that oral, not transdermal estrogen may increase the risk of venous thromboembolism in postmenopausal women."


'/>"/>

Contact: Lorinda Klein
lorindaann.klein@nyumc.org
212-404-3533
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. Autism Study Finds Significant Benefit with Hyperbaric Treatment
2. Danon Disease Can Be Quickly Fatal, Study Finds
3. NYU study finds new risk factor for melanoma in younger women
4. Study helps identify college drinkers who might continue excessive drinking as adults
5. Study finds program has improved health agencies preparedness for bioterror and disease outbreaks
6. GAO Study Links Duty Circumvention with Evasion of Food Safety Laws
7. Study IDs Variations in Black, White Genomes
8. Researchers studying hearing loss find auditory regions of the brain convert to the sense of touch
9. Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients
10. Study shows how Salmonella survives in environment
11. Study IDs Gene Variants Tied to Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) ... at Manhattan College, made the cut. The WUGC is being held in London, England this ... the gold in the men’s division, another gold in the women’s masters division, and a ...
(Date:5/2/2016)... ... May 02, 2016 , ... According to an American Psychological Association ... are sexually abused before the age of 18. Of those who survive, many still ... and others. , In her new book, Lyah! Lyah! Pants on Fyah!, she ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Centers (AAC) event, will be held at the Bellagio Hotel in Las Vegas, ... of Social Work (NASW) will be co-hosting the event. , This year’s conference ...
(Date:5/2/2016)... St. Louis, MO (PRWEB) , ... May 02, ... ... ROHO Inc., a division of Permobil, recently completed two groundbreaking studies that determined ... cushions and mattresses – are critical in the prevention of pressure injuries, which ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics ... as number five on the list of “ 5 US Cities with the Highest Plastic ... Los Angeles, and Miami. The results were calculated using a survey by RealSelf ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
Breaking Medicine Technology: